Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens

Foteini Theodorakakou, Despina Fotiou, Vasiliki Spiliopoulou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Charikleia Gakiopoulou, Erasmia Psimenou, Tina Bagratuni, Alexandra Papathoma, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos, Efstathios Kastritis

Blood (2023) 142 (Supplement 1): 6756.

https://doi.org/10.1182/blood-2023-189926

Published: 2023

Journal Articles

An Updated Analysis of Ocular Adverse Events and Vision-Related Functioning in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Maria Douvali, Stavros Gkolfinopoulos, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6720.

https://doi.org/10.1182/blood-2023-173072

Published: 2023

Journal Articles

Prevalence of Peripheral Neuropathy (PN) Among Patients with Asymptomatic Monoclonal Gammopathies: A Clinical & Electrophysiological Study

Panagiotis Zis, Rodanthi Syrigou, Stella Fanouraki, Maria Gavriatopoulou, Despina Fotiou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Maria Roussou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Evangelos Terpos, Meletios A. Dimopoulos, Efstathios Kastritis

Blood (2023) 142 (Supplement 1): 529.

https://doi.org/10.1182/blood-2023-180673

Published: 2023

Journal Articles

A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

Evangelos Terpos, Efstathios Kastritis, Argiris Symeonidis, Anastasia Pouli, Sosana Delimpasi, Eirini Katodritou, Eleftheria Hatzimichael, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Kyriaki Manousou, Maria Gavriatopoulou, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6712.

https://doi.org/10.1182/blood-2023-173185

Published: 2023

Journal Articles

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Blood (2023) 142 (Supplement 1): 3401.

https://doi.org/10.1182/blood-2023-188538

Published: 2023

Journal Articles

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Efstathios Kastritis, Vasiliki Spiliopoulou, Foteini Theodorakakou, Despina Fotiou, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Rodanthi Syrigou, Asimina Papanikolaou, Hariklia Gakiopoulou, Maria Gavriatopoulou, Evangelos Terpos, Meletios Athanasios Dimopoulos

Blood (2023) 142 (Supplement 1): 3404.

https://doi.org/10.1182/blood-2023-189521

Published: 2023

Journal Articles

Long-Term Safety and Efficacy Results of Belantamab Mafodotin Plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Part 1 Analysis from the Phase 1/2 Belard Trial

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Maria Douvali, Giorgos Psarros, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 4765.

https://doi.org/10.1182/blood-2023-173064

Published: 2023

Journal Articles

Low Levels of Circulating Tumor Cells Correlate with Favorable Clinical Outcome and Unique Biological Features in Newly Diagnosed Multiple Myeloma Patients

Ioannis V Kostopoulos, Ioannis Ntanasis-Stathopoulos, Pantelis Rousakis, Evangelos Eleutherakis-Papaiakovou, Chrysanthi Panteli, Panagiotis Malandrakis, Nikolaos Angelis, Nikolaos Kanellias, Georgia Dimitrakopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Gavriatopoulou, Efstathios Kastritis, Meletios Athanasios Dimopoulos, Ourania Tsitsilonis, Evangelos Terpos

Blood (2023) 142 (Supplement 1): 880.

https://doi.org/10.1182/blood-2023-186259

Published: 2023

Journal Articles

Evaluation of a Novel Method for the Assessment of Ocular Adverse Events and Associated Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

Blood (2023) 142 (Supplement 1): 6726.

https://doi.org/10.1182/blood-2023-173074

Published: 2023

Journal Articles

A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Argiris Symeonidis, Anastasia Pouli, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis-Papaiakovou, Ioannis Ninos, Sosana Delimpasi, Eleftheria Hatzimichael, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2023) 142 (Supplement 1): 6728.

https://doi.org/10.1182/blood-2023-173170

Published: 2023

Journal Articles

Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center

Efstathios Kastritis, Foteini Theodorakakou, Despina Fotiou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Panagiotis Malandrakis, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2022) 140 (Supplement 1): 4279–4280.

https://doi.org/10.1182/blood-2022-166185

Published: 2022

Journal Articles

Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy

Foteini Theodorakakou, Vasiliki Spiliopoulou, Despina Fotiou, Maria Roussou, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Nikolaos Kanellias, Asimina Papanikolaou, Maria Gavriatopoulou, Evangelos Terpos, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2022) 140 (Supplement 1): 4275–4276.

https://doi.org/10.1182/blood-2022-165403

Published: 2022

Journal Articles

Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial

Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Maria Gavriatopoulou, Panagiotis Malandrakis, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis Papaiakovou, Stavros Gkolfinopoulos, Kyriaki Manousou, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2022) 140 (Supplement 1): 7267–7268.

https://doi.org/10.1182/blood-2022-162208

Published: 2022

Journal Articles

Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis

Ioannis V Kostopoulos, Panagiotis Malandrakis, Ioannis Ntanasis-Stathopoulos, Pantelis Roussakis, Evangelos Eleutherakis Papaiakovou, Chrysanthi Panteli, Nikolaos Angelis, Nikolaos Kanellias, Nikolaos Orologas-Stavrou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Maria Gavriatopoulou, Efstathios Kastritis, Ourania E. Tsitsilonis, Meletios-Athanasios Dimopoulos, Evangelos Terpos

Blood (2022) 140 (Supplement 1): 1564–1565.

https://doi.org/10.1182/blood-2022-162689

Published: 2022

Journal Articles

Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies

Efstathios Kastritis, Foteini Theodorakakou, Ioannis Ntanasis-Stathopoulos, Vasiliki Spiliopoulou, Eirini Solia, Panagiotis Malandrakis, Rodanthi Syrigou, Nikoletta-Aikaterini Kokkali, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Despina Fotiou, Maria Roussou, Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2022) 140 (Supplement 1): 7324–7325.

https://doi.org/10.1182/blood-2022-165792

Published: 2022

Journal Articles

A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis Papaiakovou, Stavros Gkolfinopoulos, Kyriaki Manousou, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2022) 140 (Supplement 1): 4405–4406.

https://doi.org/10.1182/blood-2022-160014

Published: 2022

Journal Articles

A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Evangelos Terpos, Efstathios Kastritis, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, Nikolaos Kanellias, Magdalini Migkou, Foteini Theodorakakou, Vasiliki Spiliopoulou, Rodanthi Syrigou, Evangelos Eleutherakis Papaiakovou, Stavros Gkolfinopoulos, Kyriaki Manousou, Meletios A. Dimopoulos

Blood (2022) 140 (Supplement 1): 12616–12617.

https://doi.org/10.1182/blood-2022-162241

Published: 2022

Journal Articles

Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes

Efstathios Kastritis, Panagiotis Malandrakis, Vasiliki Spiliopoulou, Ioannis Ntanasis-Stathopoulos, Eirini Solia, Foteini Theodorakakou, Rodanthi Syrigou, Nikoletta-Aikaterini Kokkali, Magdalini Migkou, Evangelos Eleutherakis Papaiakovou, Despina Fotiou, Maria Roussou, Nikolaos Kanellias, Maria Gavriatopoulou, Evangelos Terpos, Meletios A. Dimopoulos

Blood (2022) 140 (Supplement 1): 7152–7153.

https://doi.org/10.1182/blood-2022-165924

Published: 2022

Journal Articles

Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Evangelos Eleutherakis Papaiakovou, Evangelos Terpos, Nikolaos Kanellias, Magdalini Migkou, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Despina Fotiou, Panagiotis Malandrakis, Foteini Theodorakakou, Panagiotis Tsirigotis, Meletios-Athanasios Dimopoulos, Efstathios Kastritis

Blood (2021) 138 (Supplement 1): 3886.

https://doi.org/10.1182/blood-2021-149499

Published: 2021

Journal Articles

Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination

Evangelos Terpos, Maria Gavriatopoulou, Ioannis Ntanasis-Stathopoulos, Alexandros Briasoulis, Sentiljana Gumeni, Panagiotis Malandrakis, Despina Fotiou, Eleni-Dimitra Papanagnou, Magdalini Migkou, Foteini Theodorakakou, Maria Roussou, Evangelos Eleutherakis-Papaiakovou, Nikolaos Kanellias, Ioannis P. Trougakos, Efstathios Kastritis, Meletios-Athanasios Dimopoulos

Blood (2021) 138 (Supplement 1): 3791.

https://doi.org/10.1182/blood-2021-144856

Published: 2021

NARROW

Curability of Light Chain (AL) Amyloidosis with Conventional Dose Regimens

An Updated Analysis of Ocular Adverse Events and Vision-Related Functioning in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

Prevalence of Peripheral Neuropathy (PN) Among Patients with Asymptomatic Monoclonal Gammopathies: A Clinical & Electrophysiological Study

A Phase 2 Study of Isatuximab in Combination with Bortezomib, Cyclophosphamide, and Dexamethasone, Followed By Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients with Multiple Myeloma and Severe Renal Impairment

Circulating Tumor Cells By Next Generation Flow Cytometry May be a New Prognostic Biomarkers Among Patients with Asymptomatic Monoclonal Gammopathies

Incidence of Second Primary Malignancies in Patients with AL Amyloidosis and the Impact of Disease Stage and Therapies

Long-Term Safety and Efficacy Results of Belantamab Mafodotin Plus Lenalidomide and Dexamethasone in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma: An Updated Part 1 Analysis from the Phase 1/2 Belard Trial

Low Levels of Circulating Tumor Cells Correlate with Favorable Clinical Outcome and Unique Biological Features in Newly Diagnosed Multiple Myeloma Patients

Evaluation of a Novel Method for the Assessment of Ocular Adverse Events and Associated Functional Impact in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in the Phase 1/2 Belard Trial

A Phase II Study of Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Multiple Myeloma Progressing on or after One Line of Lenalidomide-Containing Therapy

Prevalence of Monoclonal Gammopathy of Clinical Significance (MGCS) Among Patients with Monoclonal Gammopathies: Report from a Referral Center

Outcomes of Patients with AL Amyloidosis after Failure of Daratumumab-Based Therapy

Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial

Increased Levels of Circulating Plasma Cells in Patients with Newly Diagnosed Multiple Myeloma Are Independently Associated with Poor Prognosis

Management and Outcomes of Anti-CD38 Refractory Myeloma Patients: The Impact of Retreatment and of Subsequent Therapies

A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Daratumumab, Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Real World Efficacy and Toxicity of Selinexor: Importance of Dose Intensity and Post Progression Outcomes

Impact of Daratumumab-Containing Induction on Stem Cell Mobilization and Collection, Engraftment and Hospitalization Parameters Among Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Patients with Multiple Myeloma on Anti-CD38 or Anti-BCMA Based Regimens and Patients with Waldenstrom's Macroglobulinemia Under Rituximab or BTK Inhibitors Have a Poor Humoral Response Following COVID-19 Vaccination

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only